Afatinib Dimaleate Tablets Market to Grow at 6.3% CAGR Through 2031 According to a newly published market research report by 24LifeSciences, global Afatinib Dimaleate tablets market was valued at USD 971 million in 2024 and is projected to reach USD 1.49 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Afatinib dimaleate is an oral, small-molecule, irreversible tyrosine kinase inhibitor (TKI) that specifically targets EGFR, HER2, and HER4 signaling pathways. Its mechanism of action involves covalent binding to these receptors, providing sustained inhibition even after drug clearance. Clinical trials have repeatedly demonstrated significant efficacy in first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC), establishing it as a cornerstone therapy in precision oncology. The drug's established clinical profile and expanding approvals across global regulatory bodies continue to reinforce its critical role in modern cancer treatment protocols. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5178/afatinib-dimaleate-tablets-market